Juárez-Olguín H, Buendía-Soto E, Lares-Asseff I

Language: Spanish
References: 42
Page: 387-395
PDF size: 250.56 Kb.

ABSTRACT

During intrauterine life, the fetus can be exposed to a series of substances ingested by the mother, some of which are necessary for her health but detrimental to fetus. The noxious effects of such exposure could present immediately after exposure in the fetus or be manifested at the time of delivery and sometimes weeks after birth. The passage of drugs or nutrients across the placenta depends on some physicochemicals that have the ability to cross the placenta barrier, and thus get in contact with the fetus and produce harmful effects. Considering the physicochemical properties of the substances, the possibility of such compounds to cross the placenta barrier and thence to the fetus can be predicted. Equally, it is important to consider the characteristics of the newborn as an immature being, different from adults, when carrying out pharmacokinetic and pharmacodynamic processes. Based on the latter, it is important to know the behavior or characteristics of the fetus and the newborn in the face of drug management and above all consider the advantages and disadvantages of the use of such drugs for the care of a being yet in development, as is described in this work.

REFERENCES

1. Šlamberová R. Drugs in pregnancy: the effects on mother and her progeny. Physiol Res. 2012;61 Suppl 1:S123-35.

2. D’Alessio JG, Ramanathan J. Effects of maternal anesthesia in the neonate. Semin Perinatol, 1998;22(5):350-62.

3. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007;3(4):557-71.

4. Gokhale SG, Panchakshari MB. Maternal medication causing drug dystonia in a newborn: placental transfer of drugs. J Matern Fetal Neonatal Med. 2004;16(4):215-7.

5. Shiverick KT, Slikker W Jr, Rogerson SJ, Miller RK. Drugs and the placenta-- a workshop report. Placenta. 2003;24 Suppl A:S55-9.

6. Jauniaux E, Gulbis B. In vivo investigation of placental transfer early in human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000;92(1):45-9.

7. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev. 1999;38(1):17-39.

8. van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG. Mechanisms of drug transfer across the human placenta. Pharm World Sci. 1998;20(4):139-48.

9. Stepensky D. Prediction of drug disposition on the basis of its chemical structure. Clin Pharmacokinet. 2013;52(6):415-31.

10. Włoch S, Pałasz A, Kami´nski M. Active and passive transport of drugs in the human placenta. Ginekol Pol. 2009;80(10):772-7.

11. Vähäkangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158(3):665-78.

12. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta. 2006;27(8):861-8.

13. Eshkoli T, Sheiner E, Ben-Zvi Z, Holcberg G. Drug transport across the placenta. Curr Pharm Biotechnol. 2011;12(5):707-4.

14. Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier. Expert Opin Drug Metab Toxicol. 2012;8(10): 1263-75.

15. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther. 2000;294(2):413-20.

16. Nanovskaya TN, Patrikeeva S, Hemauer S, et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med. 2008;21(3):197-207.

17. Pollex EK, Hutson JR. Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents. Expert Opin Drug Metab Toxicol. 2011;7(3):325-39.

18. Israels LG, Israels ED. Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Semin Thromb Hemost. 1995;21(4):357-63.

19. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62(1):1-96.

20. Juárez-Olguín H, Lares-Asseff I. Antecedentes farmacológicos gestacionales implicados con la etapa neonatal. Factores que regulan el intercambio de sustancias madre-feto. Acta Pediátrica de México. 1999;20:250-6.

21. Smelt VA, Mardon HJ, Redman CW, Sim E. Acetylation of arylamines by the placenta. Eur J Drug Metab Pharmacokinet. 1997;22(4):403-8.

22. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487-514.

23. Juárez Olguín H, Sandoval Ramires E, Guille Perez A. Comportamiento del proceso LADME de los medicamentos en los niños. Acta Pediátrica de México. 2009;30:23-30.

24. Della-Giustina K, Chow G. Medications in pregnancy and lactation. Emerg Med Clin North Am. 2003;21(3):585-613.

25. Perez-Guille G, Guille-Perez A, Camacho-Vieyra A, Juárez-Olguín H, Lares Asef I. Las directrices que rigen la terapéutica farmacológica en el recién nacido. Perinatología y Reproducción Humana. 2000;14:22-31.

26. Sørensen HT, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Møller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scand. 2000;79(8):655-9.

27. Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. 2012;54(3):207-15.

28. Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev. 2004;12(4):201-21.

29. Einarson A, Shuhaiber S, Koren G. Effects of antibacterials on the unborn child: what is known and how should this influence prescribing. Paediatr Drugs. 2001;3(11):803-16.

30. Reali A, Ximenes A, Cuzzolin L, Fanos V. Antibiotic therapy in pregnancy and lactation. J Chemother. 2005;17(2):123-30.

31. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96(7):643-7.

32. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68(10):1275-81.

33. Juárez Olguín H, Lugo Goytia G, Flores Murrieta F, Ruiz García M, Lares Asseff I. Effect of treatment and additional disease on pharmacokinetics of valproic acid in children with epilepsy. Rev Inv Clin. 2010;62(6):516-23.

34. Chen L, Liu F, Yoshida S, Kaneko S. Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs? Psychiatry Clin Neurosci. 2010;64(5):460-8.

35. Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet. 2008;277(1):1-13.

36. Reali A, Ximenes A, Cuzzolin L, Fanos V. Antibiotic therapy in pregnancy and lactation. J Chemother. 2005;17(2):123-30.

37. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005;28(2):137-52.

38. Painter MJ, Minnigh MB, Gaus L, Scher M, Brozanski B, Alvin J. Neonatal phenobarbital and phenytoin binding profiles. J Clin Pharmacol. 1994;34(4):312-7.

39. Nau H, Kuhnz W, Egger HJ, Rating D, Helge H. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet. 1982;7(6):508-43.

40. Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Pilloni MD. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474-90.

41. Burdan F, Szumilo J, Klepacz R. Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009;28(2):239-44.

42. Cavalli Rde C, Lanchote VL, Duarte G, Dantas EC, de Prado MF, de Duarte LB. Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. Eur J Clin Pharmacol. 2004;60(8):569-74.